XML 134 R57.htm IDEA: XBRL DOCUMENT
v3.26.1

Discontinued operations (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Non-Current Assets Held For Sale And Discontinued Operations [Abstract] |
Disclosure of analysis of single amount of discontinued operations | The following is a reconciliation of the amounts of major classes of loss from operations classified as discontinued operations in the consolidated statements of comprehensive loss for the years ended December 31, 2025, 2024, and 2023:
| 2025 |  | 2024 |  | 2023
Revenue | $ | 9,605 |  |  | $ | 14,782 |  |  | $ | 29,050 |
Direct costs | (5,435) |  |  | (8,601) |  |  | (15,288) |
Gross profit | 4,170 |  |  | 6,181 |  |  | 13,762 |
Other income and other net gains | 5,034 |  |  | 785 |  |  | 664 |
Selling and marketing expenses | (2,215) |  |  | (3,223) |  |  | (3,413) |
Research and development expenses | (1,266) |  |  | (1,872) |  |  | (3,679) |
Impairment loss of goodwill | — |  |  | — |  |  | (3,900) |
Administrative and other operating expenses | (10,636) |  |  | (13,722) |  |  | (25,268) |
Loss from operating activities | (4,913) |  |  | (11,851) |  |  | (21,834) |
Share of (loss)/profit of equity-accounted investees, net of tax | (868) |  |  | 231 |  |  | (189) |
Gain on disposal of a subsidiary (note 34) | 2,045 |  |  | — |  |  | — |
Other finance costs | (17) |  |  | (35) |  |  | (196) |
Loss from discontinued operations before taxation | (3,753) |  |  | (11,655) |  |  | (22,219) |
Income tax credit | 22 |  |  | 235 |  |  | 440 |
Loss from discontinued operations, net of tax | $ | (3,731) |  |  | $ | (11,420) |  |  | $ | (21,779) |
Loss per share |  |  |  |  |
Basic | (0.23) |  |  | (0.57) |  |  | (1.79) |
Diluted | (0.23) |  |  | (0.57) |  |  | (1.79) |
| 2025 |  | 2024 |  | 2023
External revenue by product line |  |  |  |  |
Prevention and diagnostics - COVID-19 related and EMEA operations | $ | — |  |  | $ | 97 |  |  | $ | 13,462 |
Diagnostics - sale of precision oncology services | 9,605 |  |  | 14,685 |  |  | 15,588 |
| $ | 9,605 |  |  | $ | 14,782 |  |  | $ | 29,050 |
| 2025 |  | 2024 |  | 2023
External revenue by timing of revenue |  |  |  |  |
Goods transferred at a point in time | $ | — |  |  | $ | — |  |  | $ | 1,415 |
Services transferred at a point in time | 9,605 |  |  | 14,782 |  |  | 27,635 |
| $ | 9,605 |  |  | $ | 14,782 |  |  | $ | 29,050 |
Geographical information Information about the Group's revenue from discontinued operations from external customers is presented based on the location of the region of domicile of entities of the Group.
| 2025 |  | 2024 |  | 2023
Hong Kong | $ | 2,394 |  |  | $ | 3,938 |  |  | $ | 15,725 |
United Kingdom | 1,798 |  |  | 2,780 |  |  | 2,816 |
Taiwan | 4,835 |  |  | 7,092 |  |  | 9,325 |
Rest of the world | 578 |  |  | 972 |  |  | 1,184 |
| $ | 9,605 |  |  | $ | 14,782 |  |  | $ | 29,050 |
Other income and other net gains/(losses)
| 2025 |  | 2024 |  | 2023
Bank interest income | $ | 50 |  |  | $ | 193 |  |  | $ | 373 |
Net foreign exchange gains/(losses) | 283 |  |  | 314 |  |  | (71) |
Sundry income | 4,701 |  |  | 278 |  |  | 362 |
| $ | 5,034 |  |  | $ | 785 |  |  | $ | 664 |
Other finance costs
| 2025 |  | 2024 |  | 2023
Interest expenses on lease liabilities | $ | 17 |  |  | $ | 35 |  |  | $ | 196 |
(d)Staff costs
| 2025 |  | 2024 |  | 2023
Salaries, wages and other benefits | $ | 5,647 |  |  | $ | 7,997 |  |  | $ | 17,700 |
Contributions to defined contribution retirement plan | 441 |  |  | 565 |  |  | 597 |
Equity-settled share-based payment expenses | 1,254 |  |  | 2,004 |  |  | 354 |
| $ | 7,342 |  |  | $ | 10,566 |  |  | $ | 18,651 |
Represented by: |  |  |  |  |
Direct costs | $ | 365 |  |  | $ | 492 |  |  | $ | 3,128 |
Selling and marketing expenses | 2,003 |  |  | 2,726 |  |  | 2,536 |
Research and development expenses | 731 |  |  | 1,142 |  |  | 1,598 |
Administrative and other operating expenses | 4,243 |  |  | 6,206 |  |  | 11,389 |
Total staff costs | $ | 7,342 |  |  | $ | 10,566 |  |  | $ | 18,651 |
(e)Other items
| 2025 |  | 2024 |  | 2023
Cost of inventories | $ | 4,449 |  |  | $ | 6,903 |  |  | $ | 8,045 |
Depreciation of |  |  |  |  |
- property, plant and equipment | 407 |  |  | 1,152 |  |  | 1,632 |
- right-of-use assets | 368 |  |  | 840 |  |  | 2,015 |
Amortization of intangible assets | 666 |  |  | 1,457 |  |  | 1,467 |
Write-off on property, plant and equipment | — |  |  | — |  |  | — |
Auditor’s remuneration | 1,162 |  |  | 120 |  |  | 123 |
Freight and delivery charges | 22 |  |  | 59 |  |  | 427 |
Total depreciation and amortization charges represented by: |  |  |  |  |
Direct costs | $ | 226 |  |  | $ | 675 |  |  | $ | 904 |
Research and development expenses | 98 |  |  | 207 |  |  | 611 |
Administrative and other operating expenses | 1,117 |  |  | 2,567 |  |  | 3,599 |
Total depreciation and amortization charges | $ | 1,441 |  |  | $ | 3,449 |  |  | $ | 5,114 |
Cash flows from/(used in) discontinued operations
| 2025 |  | 2024 |  | 2023
Net cash from/(used in) operating activities | $ | 49 |  |  | $ | 5,563 |  |  | $ | (11,420) |
Net cash used in investing activities | (3,539) |  |  | (318) |  |  | (404) |
Net cash used in financing activities | (961) |  |  | (1,413) |  |  | (2,653) |
Net cash (outflows)/inflows for the year | $ | (4,451) |  |  | $ | 3,832 |  |  | $ | (14,477) |
COVID-19 diagnostic services and other DNA testing operations in the EMEA region
| 2025 |  | 2024 |  | 2023
Revenue | $ | — |  |  | $ | 97 |  |  | $ | 13,462 |
Direct costs | — |  |  | (39) |  |  | (7,357) |
Gross profit | — |  |  | 58 |  |  | 6,105 |
Other income and other net gains | 4,590 |  |  | 46 |  |  | 290 |
Selling and marketing expenses | — |  |  | (2) |  |  | (632) |
Research and development expenses | — |  |  | — |  |  | (1,189) |
Administrative and other operating expenses | (1,449) |  |  | (82) |  |  | (12,946) |
Profit/(loss) from operating activities | 3,141 |  |  | 20 |  |  | (8,372) |
Other finance costs | — |  |  | — |  |  | (122) |
Profit/(loss) from discontinued operations before taxation | 3,141 |  |  | 20 |  |  | (8,494) |
Income tax credit | — |  |  | — |  |  | 117 |
Profit/(loss) from discontinued operations, net of tax | $ | 3,141 |  |  | $ | 20 |  |  | $ | (8,377) |
Earnings/(losses) per share |  |  |  |  |
Basic | $ | 0.22 |  |  | $ | — |  |  | $ | (0.74) |
Diluted | 0.22 |  |  | — |  |  | (0.74) |
(a)Revenue Disaggregation of revenue
| 2025 |  | 2024 |  | 2023
External revenue by product line |  |  |  |  |
Prevention and diagnostics - COVID-19 related and EMEA operations | $ | — |  |  | $ | 97 |  |  | $ | 13,462 |
| 2025 |  | 2024 |  | 2023
External revenue by timing of revenue |  |  |  |  |
Goods transferred at a point in time | $ | — |  |  | $ | — |  |  | $ | 1,415 |
Services transferred at a point in time | — |  |  | 97 |  |  | 12,047 |
| $ | — |  |  | $ | 97 |  |  | $ | 13,462 |
Geographical information Information about the Group's revenue from discontinued operations from external customers is presented based on the location of the region of domicile of entities of the Group.
| 2025 |  | 2024 |  | 2023
Hong Kong | $ | — |  |  | $ | 97 |  |  | $ | 12,916 |
United Kingdom | — |  |  | — |  |  | 546 |
| $ | — |  |  | $ | 97 |  |  | $ | 13,462 |
(b)Other income and other net gains
| 2025 |  | 2024 |  | 2023
Bank interest income | $ | — |  |  | $ | — |  |  | $ | 19 |
Net foreign exchange (losses)/gains | (4) |  |  | 1 |  |  | (25) |
Sundry income | 4,594 |  |  | 45 |  |  | 296 |
| $ | 4,590 |  |  | $ | 46 |  |  | $ | 290 |
(c)Other finance costs
| 2025 |  | 2024 |  | 2023
Interest expenses on lease liabilities | $ | — |  |  | $ | — |  |  | $ | 122 |
(d)Staff costs
| 2025 |  | 2024 |  | 2023
Salaries, wages and other benefits | $ | — |  |  | $ | — |  |  | $ | 9,122 |
Contributions to defined contribution retirement plan | — |  |  | — |  |  | — |
Equity-settled share-based payment expenses | — |  |  | — |  |  | — |
| $ | — |  |  | $ | — |  |  | $ | 9,122 |
Represented by: |  |  |  |  |
Direct costs | $ | — |  |  | $ | — |  |  | $ | 2,058 |
Selling and marketing expenses | — |  |  | — |  |  | — |
Research and development expenses | — |  |  | — |  |  | — |
Administrative and other operating expenses | — |  |  | — |  |  | 7,064 |
Total staff costs | $ | — |  |  | $ | — |  |  | $ | 9,122 |
(e)Other items
| 2025 |  | 2024 |  | 2023
Cost of inventories | $ | — |  |  | $ | 38 |  |  | $ | 2,761 |
Depreciation of |  |  |  |  |
- property, plant and equipment | — |  |  | — |  |  | 98 |
- right-of-use assets | — |  |  | — |  |  | 1,025 |
Amortization of intangible assets | — |  |  | — |  |  | — |
Write-off on property, plant and equipment | — |  |  | — |  |  | — |
Auditor’s remuneration | — |  |  | — |  |  | 77 |
Freight and delivery charges | — |  |  | — |  |  | 381 |
Total depreciation and amortization charges represented by: |  |  |  |  |
Direct costs | $ | — |  |  | $ | — |  |  | $ | — |
Research and development expenses | — |  |  | — |  |  | 405 |
Administrative and other operating expenses | — |  |  | — |  |  | 718 |
Total depreciation and amortization charges | $ | — |  |  | $ | — |  |  | $ | 1,123 |
Cash flows from/(used in) discontinued operations
| 2025 |  | 2024 |  | 2023
Net cash from/(used in) operating activities | $ | 3,585 |  |  | $ | 80 |  |  | $ | (901) |
Net cash (used in)/from investing activities | (3,301) |  |  | — |  |  | 119 |
Net cash used in financing activities | — |  |  | — |  |  | (1,184) |
Net cash inflows/(outflows) for the year | $ | 284 |  |  | $ | 80 |  |  | $ | (1,966) |
B. ACT Genomics
| 2025 |  | 2024 |  | 2023
Revenue | $ | 9,605 |  |  | $ | 14,685 |  |  | $ | 15,588 |
Direct costs | (5,435) |  |  | (8,562) |  |  | (7,931) |
Gross profit | 4,170 |  |  | 6,123 |  |  | 7,657 |
Other income and other net gains | 444 |  |  | 739 |  |  | 374 |
Selling and marketing expenses | (2,215) |  |  | (3,223) |  |  | (2,781) |
Research and development expenses | (1,266) |  |  | (1,872) |  |  | (2,490) |
Impairment loss of goodwill | — |  |  | — |  |  | (3,900) |
Administrative and other operating expenses | (9,187) |  |  | (13,640) |  |  | (12,322) |
Loss from operating activities | (8,054) |  |  | (11,873) |  |  | (13,462) |
Share of (loss)/profit of equity-accounted investees, net of tax | (868) |  |  | 231 |  |  | (189) |
Gain on disposal of a subsidiary (note 34) | 2,045 |  |  | — |  |  | — |
Other finance costs | (17) |  |  | (35) |  |  | (74) |
Loss from discontinued operations before taxation | (6,894) |  |  | (11,677) |  |  | (13,725) |
Income tax credit | 22 |  |  | 235 |  |  | 323 |
Loss from discontinued operations, net of tax | $ | (6,872) |  |  | $ | (11,442) |  |  | $ | (13,402) |
Loss per share |  |  |  |  |
Basic | (0.45) |  |  | (0.57) |  |  | (1.05) |
Diluted | (0.45) |  |  | (0.57) |  |  | (1.05) |
(a)Revenue Disaggregation of revenue
| 2025 |  | 2024 |  | 2023
External revenue by product line |  |  |  |  |
Diagnostics - sale of precision oncology services | $ | 9,605 |  |  | $ | 14,685 |  |  | $ | 15,588 |
| 2025 |  | 2024 |  | 2023
External revenue by timing of revenue |  |  |  |  |
Services transferred at a point in time | $ | 9,605 |  |  | $ | 14,685 |  |  | $ | 15,588 |
Geographical information Information about the Group's revenue from discontinued operations from external customers is presented based on the location of the region of domicile of entities of the Group.
| 2025 |  | 2024 |  | 2023
Hong Kong | $ | 2,394 |  |  | $ | 3,840 |  |  | $ | 2,809 |
United Kingdom | 1,798 |  |  | 2,780 |  |  | 2,270 |
Taiwan | 4,835 |  |  | 7,092 |  |  | 9,325 |
Rest of the world | 578 |  |  | 973 |  |  | 1,184 |
| $ | 9,605 |  |  | $ | 14,685 |  |  | $ | 15,588 |
(b)Other income and other net gains
| 2025 |  | 2024 |  | 2023
Bank interest income | $ | 50 |  |  | $ | 193 |  |  | $ | 354 |
Net foreign exchange gains/(losses) | 287 |  |  | 313 |  |  | (46) |
Sundry income | 107 |  |  | 233 |  |  | 66 |
| $ | 444 |  |  | $ | 739 |  |  | $ | 374 |
(c)Other finance costs
| 2025 |  | 2024 |  | 2023
Interest expenses on lease liabilities | $ | 17 |  |  | $ | 35 |  |  | $ | 74 |
(d)Staff costs
| 2025 |  | 2024 |  | 2023
Salaries, wages and other benefits | $ | 5,647 |  |  | $ | 7,997 |  |  | $ | 8,578 |
Contributions to defined contribution retirement plan | 441 |  |  | 565 |  |  | 597 |
Equity-settled share-based payment expenses | 1,254 |  |  | 2,004 |  |  | 354 |
| $ | 7,342 |  |  | $ | 10,566 |  |  | $ | 9,529 |
Represented by: |  |  |  |  |
Direct costs | $ | 365 |  |  | $ | 492 |  |  | $ | 1,070 |
Selling and marketing expenses | 2,003 |  |  | 2,726 |  |  | 2,536 |
Research and development expenses | 731 |  |  | 1,142 |  |  | 1,598 |
Administrative and other operating expenses | 4,243 |  |  | 6,206 |  |  | 4,325 |
Total staff costs | $ | 7,342 |  |  | $ | 10,566 |  |  | $ | 9,529 |
(e)Other item s
| 2025 |  | 2024 |  | 2023
Cost of inventories | $ | 4,449 |  |  | $ | 6,866 |  |  | $ | 5,284 |
Depreciation of |  |  |  |  |
- property, plant and equipment | 408 |  |  | 1,152 |  |  | 1,534 |
- right-of-use assets | 367 |  |  | 840 |  |  | 990 |
Amortization of intangible assets | 666 |  |  | 1,457 |  |  | 1,467 |
Write-off on property, plant and equipment | — |  |  | — |  |  | — |
Auditor’s remuneration | 1,162 |  |  | 120 |  |  | 46 |
Freight and delivery charges | 22 |  |  | 59 |  |  | 46 |
Total depreciation and amortization charges represented by: |  |  |  |  |
Direct costs | $ | 226 |  |  | $ | 675 |  |  | $ | 904 |
Research and development expenses | 98 |  |  | 207 |  |  | 206 |
Administrative and other operating expenses | 1,117 |  |  | 2,567 |  |  | 2,881 |
Total depreciation and amortization charges | $ | 1,441 |  |  | $ | 3,449 |  |  | $ | 3,991 |
Cash flows (used in)/from discontinued operations
| 2025 |  | 2024 |  | 2023
Net cash (used in)/from operating activities | $ | (3,536) |  |  | $ | 5,483 |  |  | $ | (10,519) |
Net cash used in investing activities | (238) |  |  | (318) |  |  | (523) |
Net cash used in financing activities | (961) |  |  | (1,413) |  |  | (1,469) |
Net cash (outflows)/inflows for the year | $ | (4,735) |  |  | $ | 3,752 |  |  | $ | (12,511) |

X
- Definition The disclosure of the analysis of the single amount of discontinued operations. [Refer: Discontinued operations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2025-01-01 -Paragraph 33 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non-Current Assets Held For Sale And Discontinued Operations + References No definition available. + Details
Name: | pre_NonCurrentAssetsHeldForSaleAndDiscontinuedOperationsAbstract
Namespace Prefix: | pre_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration